Polyclonal Antibody to Antigen Peptide Transporter 2 (TAP2)
| Code | Size | Price |
|---|
| PAD112Ra01-20ul | 20ul | £92.00 |
Quantity:
| PAD112Ra01-100ul | 100ul | £173.00 |
Quantity:
| PAD112Ra01-200ul | 200ul | £234.00 |
Quantity:
| PAD112Ra01-1ml | 1ml | £539.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Antibody Clonality: Polyclonal
Regulatory Status: RUO
Target Species: Rat
Applications:
- Enzyme-Linked Immunosorbent Assay (ELISA)
- Immunocytochemistry (ICC)
- Immunohistochemistry- Frozen Section (IHC-F)
- Immunohistochemistry- Paraffin Embedded (IHC-P)
- Western Blot (WB)
Documents
Further Information
Alternative Names:
ABC18; ABCB3; APT2; PSF2; RING11; Y1; ATP-binding cassette sub-family B member 3; Peptide supply factor 2; Peptide transporter involved in antigen processing 2
Buffer Formulation:
PBS, pH7.4, containing 0.02% NaN3, 50% glycerol.
Item Name:
Antigen Peptide Transporter 2
Reactivity:
Mu;
Source:
Polyclonal antibody preparation
Usage:
Western blotting: 0.2-2ug/mL;1:250-2500
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
Immunohistochemistry: 5-20ug/mL;1:25-100
Immunocytochemistry: 5-20ug/mL;1:25-100
Optimal working dilutions must be determined by end user.
Related Products
| Product Name | Product Code | Supplier | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Immunogen | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Recombinant Antigen Peptide Transporter 2 (TAP2) | RPD112Ra01 | Cloud-Clone Corp. | Summary Details | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||